Eli Lilly and Company (BKK:LLY80)

Market Cap	20.42T
Revenue (ttm)	1.73T
Net Income (ttm)	448.19B
Shares Out	n/a
EPS (ttm)	496.67
PE Ratio	45.57
Forward PE	25.44
Dividend	0.00 (0.19%)
Ex-Dividend Date	May 16, 2025

Volume	11,504,400
Average Volume	4,497,185
Open	1.090
Previous Close	1.080
Day's Range	1.070 - 1.150
52-Week Range	1.010 - 1.360
Beta	n/a
RSI	41.39
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: LLY80

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD